Stephen Liu: Report on brain metastases in patients with KRAS NSCLC

Stephen Liu shared on X/Twitter:

“Report on brain metastases in patients with KRAS NSCLC in phase II/III trials Lung Cancer Journal from Dr. Sukhmani Padda. In patients with baseline brain metastases, 27.4% had CNS progression on docetaxel (12m CNS DCR 75.8%); 8.4% without brain metastases developed new metastases on docetaxel.”

Source: Stephen Liu/X

Stephen Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies.

His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer. Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.